Health Care·Biotechnology·$4.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | +30.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.25 | N/A | +30.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly regarding EPS. They emphasized ongoing efforts to develop their product pipeline.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.
The earnings report shows that Amicus Therapeutics exceeded expectations on EPS, which contributed to a positive stock reaction, with shares rising 4.38%. However, the lack of revenue data and forward guidance may leave investors cautious. Overall, the company appears to be making progress in its operations, but clarity on future performance is needed.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COSTCO WHSL CORP NEW
Mar 12, 2013